Compare Z & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | Z | SRRK |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.8B |
| IPO Year | 2014 | 2018 |
| Metric | Z | SRRK |
|---|---|---|
| Price | $33.11 | $53.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 13 |
| Target Price | ★ $79.45 | $56.17 |
| AVG Volume (30 Days) | ★ 3.8M | 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,076,794,000.00 | N/A |
| Revenue This Year | $17.77 | N/A |
| Revenue Next Year | $13.31 | $534.24 |
| P/E Ratio | $189.67 | ★ N/A |
| Revenue Growth | ★ 27.19 | N/A |
| 52 Week Low | $29.23 | $27.07 |
| 52 Week High | $93.88 | $58.49 |
| Indicator | Z | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 59.70 |
| Support Level | $29.31 | $45.81 |
| Resistance Level | $34.46 | $58.49 |
| Average True Range (ATR) | 1.81 | 2.36 |
| MACD | 0.02 | 0.54 |
| Stochastic Oscillator | 48.62 | 91.97 |
Zillow Group Inc is a real estate technology company offering a digital platform that connects real estate customers with sellers, agents, loan officers, and other real estate-related professionals. With its tools and resources, Zillow helps real estate professionals grow their businesses, and for renters and housing providers, it offers a marketplace along with a set of end-to-end products and services to streamline applications, leases, payments, and more. The group operates various brands such as Zillow, Zillow Home Loans, Zillow Rentals, Zillow New Construction, Trulia, StreetEasy, Out East, HotPads, Follow Up Boss, ShowingTime, dotloop, and Zillow Closing. Its ecosystem spans the entire home journey from shopping to renting, buying, selling, and financing real estate.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.